Interleukin-1 receptor antagonist is detectable in human carotid artery plaques and is related to triglyceride levels and Chlamydia pneumoniae IgA antibodies

被引:19
|
作者
Gottsäter, A [1 ]
Forsblad, J
Mätzsch, T
Persson, K
Ljungcrantz, I
Ohlsson, K
Lindgärde, F
机构
[1] Lund Univ, Malmo Univ Hosp, Dept Vasc Dis, S-20502 Malmo, Sweden
[2] Lund Univ, Malmo Univ Hosp, Dept Clin Microbiol, Malmo, Sweden
[3] Lund Univ, Malmo Univ Hosp, Dept Surg Pathophysiol, Malmo, Sweden
关键词
carotid artery stenosis; Chlamydia pneumoniae; interleukin-1 receptor antagonist; interleukin-1; beta; triglycerides;
D O I
10.1046/j.1365-2796.2002.00926.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To investigate whether the interleukin-1 receptor antagonist (Il-1ra) and interleukin-1beta (Il-1beta) can be detected in human carotid artery tissue, and whether their presence is related to evidence of Chlamydia pneumoniae infection, risk factors for atherosclerosis, and clinical data. Setting. Departments of Vascular Diseases and Surgical Pathophysiology, University Hospital, Malmo, Sweden. Subjects. A total of 66 patients undergoing carotid endarterectomy (median age 74, range 53-89 years, 20 women). Il-1beta and Il-1ra were studied in carotid artery plaques and in Il-1ra in serum. Results. Interleukin-1 receptor antagonist was detected in mononuclear cells in plaques from 37/ 66 (56%) patients. Patients with Il-1ra in plaques showed higher [2.04 (1.70-3.14) mmol L-1 vs. 1.69 (1.09-1.99) mmol L-1; P < 0.05] serum(s-)triglyceride(tg) levels, and a higher frequency of IgA seropositivity for C. pneumoniae (76% vs. 52%: P < 0.05) than those without. S-Il-1ra levels correlated with s-tg levels (r = 0.38; P = 0.047). There were no differences between patients with and without Il-1ra in plaques concerning s-Il-1ra, blood(b-)haemoglobin or leucocyte count, s-cholesterol, b-glucose, blood pressure, IgG seropositivity for C. pneumoniae, prevalence of neurological symptoms preceding operation, smoking, or diabetes mellitus. There were no differences in frequency of Il-1ra in plaques or in s-Il-1ra levels between patients with symptomatic and asymptomatic stenosis, between smokers and nonsmokers, or between diabetic and nondiabetic patients. Il-1beta was not detected in plaques in the current study. Conclusion. Interleukin-1 receptor antagonist can be detected in human atherosclerotic carotid artery plaques, and is related to s-triglyceride levels and IgA seropositivity for C. pneumoniae, but not to prevalence of neurological symptoms related to embolization.
引用
收藏
页码:61 / 68
页数:8
相关论文
共 50 条
  • [21] INTERLEUKIN-1 RECEPTOR ANTAGONIST INHIBITS INTERLEUKIN-1 INDUCED CYTOKINE SYNTHESIS BY HUMAN MONOCYTES
    GRANOWITZ, EV
    CLARK, BD
    VANNIER, E
    CALLAHAN, MV
    DINARELLO, CA
    CLINICAL RESEARCH, 1991, 39 (02): : A462 - A462
  • [22] EXPRESSION OF INTERLEUKIN-1 AND INTERLEUKIN-1 RECEPTOR ANTAGONIST BY HUMAN RHEUMATOID SYNOVIAL TISSUE MACROPHAGES
    KOCH, AE
    KUNKEL, SL
    CHENSUE, SW
    HAINES, GK
    STRIETER, RM
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1992, 65 (01): : 23 - 29
  • [23] LIPOPOLYSACCHARIDE INDUCES HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST AND INTERLEUKIN-1 PRODUCTION IN THE SAME CELL
    ANDERSSON, J
    BJORK, L
    DINARELLO, CA
    TOWBIN, H
    ANDERSSON, U
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (10) : 2617 - 2623
  • [24] Effects of treatment with interleukin-1 receptor antagonist on endogenous interleukin-1 levels in normal and irradiated mice
    Bugarski, D
    Jovcic, G
    Kataranovski, M
    Ivanovic, Z
    Petakov, M
    Stojanovic, N
    Milenkovic, P
    PHYSIOLOGICAL RESEARCH, 2000, 49 (03) : 355 - 362
  • [25] Gingival crevicular interleukin-1 and interleukin-1 receptor antagonist levels in periodontally healthy and diseased sites
    Ishihara, Y
    Nishihara, T
    Kuroyanagi, T
    Shirozu, N
    Yamagishi, E
    Ohguchi, M
    Koide, M
    Ueda, N
    Amano, K
    Noguchi, T
    JOURNAL OF PERIODONTAL RESEARCH, 1997, 32 (06) : 524 - 529
  • [26] Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration
    Meyer, Nuala J.
    Reilly, John P.
    Anderson, Brian J.
    Palakshappa, Jessica A.
    Jones, Tiffanie K.
    Dunn, Thomas G.
    Shashaty, Michael G. S.
    Feng, Rui
    Christie, Jason D.
    Opal, Steven M.
    CRITICAL CARE MEDICINE, 2018, 46 (01) : 21 - 28
  • [27] Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease
    Francis, SE
    Camp, NJ
    Dewberry, RM
    Gunn, J
    Syrris, P
    Carter, ND
    Jeffery, S
    Kaski, JC
    Cumberland, DC
    Duff, GW
    Crossman, DC
    CIRCULATION, 1999, 99 (07) : 861 - 866
  • [28] HUMAN SERUM IGA AND TRIGGERING OF FC-ALPHA RECEPTOR INDUCE INTERLEUKIN-1 RECEPTOR ANTAGONIST AND MODULATE MONOCYTES
    EIBL, MM
    WOLF, HM
    SAMSTAG, A
    FISCHER, MB
    AHMAD, RU
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 246 - 246
  • [29] ELABORATION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST BY HUMAN BRONCHOGENIC CARCINOMAS
    SMITH, DR
    KUNKEL, SL
    STANDIFORD, TJ
    LUKACS, NW
    ROLFE, MW
    ORRINGER, MB
    WHYTE, RI
    BURDICK, MD
    DANFORTH, JM
    GILBERT, AR
    STRIETER, RM
    FASEB JOURNAL, 1993, 7 (03): : A268 - A268
  • [30] SOLUTION STRUCTURE OF HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN
    STOCKMAN, BJ
    SCAHILL, TA
    STRAKALAITIS, NA
    BRUNNER, DP
    YEM, AW
    DEIBEL, MR
    FEBS LETTERS, 1994, 349 (01): : 79 - 83